You are here: Industry Insights > SII

News List

Novavax, SII File COVID Vax EUA in South Africa contractpharma
January 10, 2022
If authorized, the vaccine will be manufactured by and commercialized by SII in South Africa under the brand name Covovax.
India seeks additional data from Serum Institute for Covovax approval Pharmaceutical-Technology
November 30, 2021
The Subject Expert Committee (SEC) on Covid-19 of India’s Central Drugs Standard Control Organisation (CDSCO) has sought more data from the Serum Institute of India (SII) for the Covid-19 vaccine Covovax.
SII urges govt to fast-track movement of increasing Covishield stock ExpressPharma
November 24, 2021
The Serum Institute of India (SII) has urged the government to fast-track Covishield movement citing the difficulties being faced in production and cold chain space planning for other vaccines...
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine prnasia
August 06, 2021
Novavax, Inc. today announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
CII to work with Serum Institute of India to expand vaccination across small towns and rural areas expresspharma
August 02, 2021
As part of the pan-India vaccine-demand aggregation exercise, CII undertook a survey with response from over 3,000 companies in 196 cities. This identified a requirement of over seven million single-dose vaccines.
CDSCO grants permission to three private COVID-19 vaccines for restricted use in emergency situation expresspharma
July 21, 2021
The information was given today by Mansukh Mandaviya, Union Minister of Chemicals and Fertilizers, in a written reply in the Lok Sabha.
Serum Institute to start manufacturing Sputnik vaccine in September expresspharma
July 14, 2021
The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September, RDIF said.
SII to commence manufacturing of Sputnik COVID-19 vaccine in September expresspharma
July 14, 2021
As per the agreement between RDIF and SII, the parties intend to produce over 300 million doses of the vaccine in India per year.
Covishield approval to be considered on receiving marketing authorisation application: EMA expresspharma
June 30, 2021
The Covishield vaccine “does not currently have a marketing authorisation” in Europe and the matter would be considered when an application is received for it, the European Medicines Agency (EMA) said.
Urgently trying to work with AstraZeneca, SII, Indian govt to resume shipments of COVID-19 vaccines: WHO expresspharma
June 21, 2021
The WHO is “urgently” trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of COVID-19 vaccines to countries that had to suspend the rollout of second doses of vaccines amid the ...

Previous page 1 2 3 4 5 6 Next page